- Home
- CHY vs SVRA Comparison
CHY vs SVRA Comparison
Compare CHY & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CHY | SVRA |
|---|---|---|
| Founded | 2003 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.3B |
| IPO Year | 2003 | 2009 |
Fundamental Metrics
Financial Performance| Metric | CHY | SVRA |
|---|---|---|
| Price | $13.74 | $6.07 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $7.33 |
| AVG Volume (30 Days) | 148.4K | ★ 2.0M |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | ★ 10.11% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $430.87 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.41 | $2.25 |
| 52 Week High | $13.67 | $7.01 |
Technical Indicators
Market Signals| Indicator | CHY | SVRA |
|---|---|---|
| Relative Strength Index (RSI) | 65.20 | 58.79 |
| Support Level | $11.27 | $5.86 |
| Resistance Level | N/A | $6.15 |
| Average True Range (ATR) | 0.21 | 0.29 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 79.11 | 56.92 |
Price Performance
Historical ComparisonAbout CHY Calamos Convertible and High Income Fund
Calamos Convertible & High Income Fund is a diversified, closed-end management investment company. Its objective is to provide total return through a combination of capital appreciation and current income. The firm invests in a diversified portfolio of convertible securities and high-yield securities.
About SVRA Savara Inc.
Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).